Abstract Body

Integrase Inhibitors (INI) are now the first-line treatment for people living with HIV, including children. Clinical trials among adults have risen concerns regarding weight gain in patients starting or switching to INI. Clinical trials in children and adolescents are ongoing, as there is concern regarding weight gain in this population, characterized by important changes in body composition. We aim to describe anthropometric evolution of children and adolescents on INI versus other regimens.

Within the Spanish Cohort of Pediatric HIV, patients below 24 years of age started on or switched to a dolutegravir containing regimen up to December 2019 and with at least 12 months follow-up data were included in the study. A control group of patients not receiving INI was recruited from the same cohort. Anthropometrics were collected every 6 months for up to 24 months of follow-up. The 2010 Spanish growth charts were used to estimate BMI-Z-Score.

A total of 179 patients were included, 66.3% female, 54.2% Caucasian, with a median age of 14 years (12.0 -17.3). Among the 83 patients on dolutegravir, 62.1% corresponded to treatment switch and treatment regimen included abacavir plus lamivudine in 80%. In the control group, treatment was based on efavirenz (35%), protease inhibitors (26%) or elvitegravir (35%), mostly combined with tenofovir-alafenamide fumarate (TAF) (43%), abacavir/lamivudine (28%) or tenofovir (17%). Both groups were comparable regarding age, gender distribution, ethnicity, BMI at baseline and CDC stage. The median follow-up was 20.7months [17.1- 22.9]. Over follow-up, no significant increase in weight z-score and/or BMI was observed. Sensitivity analysis by gender and ethnicity did not show differences either, as shown in Figure 1.

In this cohort study including children and adolescents, no association between exposure to dolutegravir and weight gain was found. Although these data are reassuring, larger studies and longer follow-up are needed in order to address the long-term effects of dolutegravir on weight during the unique period of adolescence.